RICHELDI, Luca
 Distribuzione geografica
Continente #
NA - Nord America 13281
EU - Europa 5264
AS - Asia 750
SA - Sud America 17
AF - Africa 16
Continente sconosciuto - Info sul continente non disponibili 16
OC - Oceania 14
Totale 19358
Nazione #
US - Stati Uniti d'America 13239
GB - Regno Unito 2282
SE - Svezia 763
IT - Italia 615
UA - Ucraina 473
DE - Germania 457
CN - Cina 302
TR - Turchia 271
FI - Finlandia 188
BG - Bulgaria 165
FR - Francia 163
IN - India 45
BE - Belgio 44
RU - Federazione Russa 39
CA - Canada 34
VN - Vietnam 28
KR - Corea 25
IE - Irlanda 18
IR - Iran 18
EU - Europa 13
NL - Olanda 13
IQ - Iraq 12
ZA - Sudafrica 12
AU - Australia 11
JP - Giappone 8
MY - Malesia 8
ID - Indonesia 7
PK - Pakistan 7
CH - Svizzera 6
CL - Cile 6
MX - Messico 6
ES - Italia 5
HK - Hong Kong 5
PL - Polonia 5
BR - Brasile 4
CO - Colombia 4
GR - Grecia 4
RO - Romania 4
TH - Thailandia 4
A2 - ???statistics.table.value.countryCode.A2??? 3
NO - Norvegia 3
NZ - Nuova Zelanda 3
SG - Singapore 3
TW - Taiwan 3
AT - Austria 2
BZ - Belize 2
DK - Danimarca 2
HR - Croazia 2
LV - Lettonia 2
MG - Madagascar 2
NG - Nigeria 2
PE - Perù 2
PT - Portogallo 2
AL - Albania 1
AR - Argentina 1
BD - Bangladesh 1
BY - Bielorussia 1
CZ - Repubblica Ceca 1
EE - Estonia 1
KH - Cambogia 1
MO - Macao, regione amministrativa speciale della Cina 1
OM - Oman 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
SM - San Marino 1
Totale 19358
Città #
Fairfield 2176
Southend 2014
Woodbridge 1472
Houston 1133
Jacksonville 955
Chandler 921
Ashburn 822
Seattle 811
Dearborn 752
Wilmington 707
Ann Arbor 695
Cambridge 690
Nyköping 452
San Diego 191
Modena 179
Princeton 172
Sofia 164
Eugene 158
Izmir 123
Beijing 113
Des Moines 57
London 56
Redwood City 49
Bremen 46
Brussels 44
Helsinki 33
Boardman 29
Norwalk 28
Milan 27
Philadelphia 27
Phoenix 27
Dong Ket 26
Hefei 26
Kunming 20
Falls Church 19
San Mateo 19
Dublin 17
Leawood 17
San Francisco 17
Guangzhou 15
Nanjing 15
Bari 14
Jinan 14
Indiana 13
Palermo 13
Rome 13
Mountain View 12
New York 12
Verona 11
Chicago 10
Nanchang 10
Toronto 10
Ottawa 9
Seongnam 9
Zhengzhou 8
Chennai 7
Napoli 7
Perugia 7
Saint Petersburg 7
San Jose 7
Seoul 7
Andover 6
Auburn Hills 6
Basrah 6
Islington 6
Paris 6
Pioltello 6
Turin 6
Ardabil 5
Chongqing 5
Durban 5
Fuzhou 5
Gurgaon 5
Hangzhou 5
Zanjan 5
Borås 4
Brisbane 4
Chengdu 4
Florence 4
Genoa 4
Indianapolis 4
Kundan 4
Los Angeles 4
Naples 4
Sesto San Giovanni 4
Shaoxing 4
Shenyang 4
Tokyo 4
Villeurbanne 4
Wuhan 4
Yellow Springs 4
Augusta 3
Borgosesia 3
Campobasso 3
Canberra 3
Castelvetrano 3
Changsha 3
Città di Castello 3
Dosimo 3
Frankfurt am Main 3
Totale 15682
Nome #
Multidrug-resistant tuberculosis outbreak in an Italian prison: Tolerance of pyrazinamide plus levofloxacin prophylaxis and serial interferon gamma release assays 645
Malattie infiltrative diffuse del polmone 259
Structured reporting for fibrosing lung disease: a model shared by radiologist and pulmonologist 239
Non-steroid agents for idiopathic pulmonary fibrosis 235
Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study 208
Diagnosis of occult tuberculosis in hematological malignancy by enumeration of antigen-specific T cells. 204
"Velcro-type" crackles predict specific radiologic features of fibrotic interstitial lung disease 198
Efficacy of hormonal suppression in a patient with chyluria due to lymphangioleiomyomatosis 195
Atypical lipomatous tumour (lipoma-like well-differentiated liposarcoma) arising in a pulmonary hamartoma and clinically presenting with pneumothorax 194
Prior tuberculin skin testing does not boost QuantiFERON-TB results in paediatric contacts 192
Clinical use of Levofloxacin in the long-term treatment of drug resistant tuberculosis. 192
Use of Pirfenidone in Idiopathic Pulmonary Fibrosis: A Case Study 191
Levels of circulating endothelial cells are low in idiopathic pulmonary fibrosis and are further reduced by anti-fibrotic treatments 190
A culture-proven case of community-acquired Legionella pneumonia apparently classified as nosocomial: diagnostic and public health implications 177
Room size is the major determinant for tuberculin conversion in health care workers exposed to a multidrug-resistant tuberculosis patient 176
Lung cancer in scleroderma: results from an Italian rheumatologic center and review of the literature. 176
Unexpected identification of bilateral masses in an asymptomatic heavy smoker. 174
Aortic pulse wave velocity measurement in systemic sclerosis patients. 174
T cell-based tracking of multidrug resistant tuberculosis infection after brief exposure 170
Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis 169
Occurrence of idiopathic pulmonary fibrosis during immunosuppressive treatment: a case report 168
Role Of The QFT-IT Assay For The Diagnosis Of Latent Tuberculosis Infection Among Adult Immigrants 168
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis 167
Rifabutin for treating pulmonary tuberculosis. 166
Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials 164
Amyotrophic lateral sclerosis and sarcoidosis: a difficult differential diagnosis. 163
Assessing the treatment effect from multiple trials in idiopathic pulmonary fibrosis. 162
Pulmonary fibrosis and the many faces of UIP 159
Comparison of the tubercolin skin test and the ellispot blood test for the diagnosis of latent tuberculosis infection in pre-transplant dialysis patients 159
T-cell-based diagnosis of neonatal multidrug-resistant latent tuberculosis infection. 158
New approaches to the design of clinical trials in idiopathic pulmonary fibrosis 158
Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis. 158
Using ELISpot technology to improve the diagnosis of tuberculosis infection: from the bench to the T-SPOT.TB assay 156
A quantitative proteomic approach to identify significantly altered protein networks in the serum of patients with lymphangioleiomyomatosis (LAM) 156
Mindfulness-based stress reduction in patients with interstitial lung diseases: a pilot, single-centre observational study on safety and efficacy 155
Bronchoalveolar lavage and response to cyclophosphamide in scleroderma alveolitis. 154
Novel drug targets for idiopathic pulmonary fibrosis 154
Lung fibrosis, bone marrow fibrosis and liver cirrhosis: A Short Telomere Syndrome or a casual association? 153
Triggering receptor expressed on myeloid cells: role in the diagnosis of lung infections 152
Environmental triggers and susceptibility factors in idiopathic granulomatous diseases. 152
Management of idiopathic pulmonary fibrosis. 150
Sarcoidosis: challenging diagnostic aspects of an old disease. 149
Emerging drugs for idiopathic pulmonary fibrosis. 149
MDR1 C3435T genetic polymorphism does not influence the response to antiretroviral therapy in drug-naive HIV-positive patients 146
Management of Idiopathic Pulmonary Fibrosis 144
Quantiferon-TB Gold In-Tube Tests In Hospital Health Care Workers: A Five Years Experience 143
MOLECULAR DIAGNOSIS OF TUBERCULOSIS 142
The big clinical trials in idiopathic pulmonary fibrosis. 141
Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. 140
Treating idiopathic pulmonary fibrosis: current opportunities and future challenges. 140
Macrolides in the treatment of asthma and cystic fibrosis 139
Home Oxygen Saturation Monitoring And Quality Of Life Evaluation In Patients With Idiopathic Pulmonary Fibrosis: Preliminary Results From A Prospective Multicenter Trial 138
HRCT Patterns Of Usual Interstitial Pneumonia In Rheumatoid Lung 138
Immunomodulatory agents for idiopathic pulmonary fibrosis. 137
Prevalence and prognosis of unclassifiable interstitial lung disease 137
Repeated Quantiferon-TB Gold In-Tube Tests In Routine Clinical Practice: A Five Years Experience 136
Performance of tests for latent tuberculosis in different groups of immunocompromised patients. 135
Idiopathic pulmonary fibrosis: current challenges and future perspectives 134
An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. 133
The role of biomarkers in low respiratory tract infections. 133
Genetic testing in diffuse parenchymal lung disease 133
An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias 132
Hot of the breath: mortality as a primary end-point in IPF treatment trials: the best is the enemy of the good 132
Role of the quantiferon-TB test in ruling out pleural tuberculosis: a multi-centre study. 130
End of an ERA: lessons from negative clinical trials in idiopathic pulmonary fibrosis. 129
Idiopathic pulmonary fibrosis: diagnostic pitfalls and therapeutic challenges. 128
Mapping the future for pulmonary fibrosis: report from the 17th International Colloquium on Lung and Airway Fibrosis 128
Pirfenidone in idiopathic pulmonary fibrosis: the CAPACITY program. 128
Smoking-related interstitial lung disease 127
Fibulin-1 predicts disease progression in patients with idiopathic pulmonary fibrosis 126
Exploring the immune response against Mycobacterium tuberculosis for a better diagnosis of the infection. 123
The complex interrelationships between chronic lung and liver disease: a review. 120
Acute exacerbations of chronic obstructive pulmonary disease: are antibiotics needed? 120
Prevalence Of Subclinical Liver Fibrosis Among Patients With Idiopathic Pulmonary Fibrosis 120
Interferon gamma assays for tuberculosis 119
Immunogenetic basis of environmental lung disease: lessons from the berylliosis model 119
Early diagnosis of subclinical multi drug-resistant tuberculosis 118
HLA-DPB1 Glutamate 69: a genetic marker of beryllium disease 117
To BAL or not to BAL: is this a problem in diagnosing IPF? 117
Idiopathic pulmonary fibrosis: recent trials and current drug therapy 117
Churg-Strauss syndrome in a case of asthma 116
RHEUMATOID ARTHRITIS RELATED INTERSTITIAL LUNG DISEASE. RADIOLOGICAL PATTERNS AND CORRELATIONS WITH CLINICAL, SEROLOGICAL AND DEMOGRAPHIC FEATURES OF DISEASE 116
Impact of a T cell-based blood test for tuberculosis infection on clinical decision-making in routine practice 115
Performance of commerical blood tests for the diagnosis of latent tuberculosis infection in children and adolescents 115
Tuberculosis diagnostic tests: Sensitivity, specificity, and comparing apples with apples 114
Macrolides for chronic asthma. 113
Screening dell’infezione tubercolare latente in operatori sanitari con QuantiFERON-TB e test cutaneo tubercolinico [Screening of latent tuberculosis infection in health care workers by QuantiFERON-TB and tuberculin skin test] 112
Tuberculosis infection in foreign-born children: a screening survey based on skin and blood testing. 111
An update on the diagnosis of tuberculosis infection 110
Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial 110
Interaction of genetic and exposure factors in the prevalence of berylliosis 109
Corticosteroid and immunomodulatory agents in idiopathic pulmonary fibrosis 109
A multicentre evaluation of the accuracy and performance of IP-10 for the diagnosis of infection with M. tuberculosis. 109
Macrolides for chronic asthma. 109
Identification of two new DPB1 alleles, DPB1*7701 and *7801, by sequence-based typing 108
Il cloroformio nell'aria alveolare di frequentatori di piscine coperte. 107
Mycobacterium tuberculosis induces CCL18 expression in human macrophages 107
Rapid identification of Mycobacterium tuberculosis infection 106
Inactivation of polymerase inhibitors for Mycobacterium tuberculosis DNA amplification in sputum by using capture resin 105
Repeated tuberculin testing does not induce false positive ELISPOT results 103
Totale 15031
Categoria #
all - tutte 43651
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 43651


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2017/201816 0000 00 00 00016
2018/20192671 6320426155 181169 22027 55259651661
2019/20205468 407325240328 613839 921521 519190302263
2020/20213561 347180355291 366262 292444 165417243199
2021/20222903 86488275221 5987 200108 293208525353
2022/20232650 324274169241 317402 61297 339891289
Totale 19553